ANG2 ANTIBODIES

The present invention relates to antibodies that bind human angiopoietin-2 (Ang2), and may be useful for treating cancer alone and in combination with VEGF pathway inhibitors, especially cancer driven by VEGFR2 and Ang2, including gastric, hepatocellular carcinoma, ovarian, colorectal, and breast ca...

Full description

Saved in:
Bibliographic Details
Main Authors Jianghuai XU, Donmienne Doen Mun LEUNG
Format Patent
LanguageEnglish
Spanish
Published 07.03.2017
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to antibodies that bind human angiopoietin-2 (Ang2), and may be useful for treating cancer alone and in combination with VEGF pathway inhibitors, especially cancer driven by VEGFR2 and Ang2, including gastric, hepatocellular carcinoma, ovarian, colorectal, and breast cancers. La presente invención se refiere a anticuerpos que se unen a angiopoyetina-2 humana (Ang2) y pueden ser útiles para tratar cáncer solo y en combinación con inhibidores de la trayectoria de VEGF, especialmente cáncer accionado por VEGFR2 y Ang2, que incluyen cáncer gástrico, carcinoma hepatocelular, de ovario, colorrectal y de mama.
Bibliography:Application Number: MX20160015151